ACET Stock — Adicet Bio Inc

Adicet Bio Inc (ACET)

Updated October 2, 2026.

ACET is a Stock. Total return is -99.7% over the past 8.7 years, 306.4 points behind SPY at 206.7%.

Adicet Bio is a clinical stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, with lead candidate prulacabtagene leucel targeting CD20 for autoimmune conditions and ADI-212 in development for prostate cancer. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage biotechnology development, though it carries the risks associated with clinical stage companies without approved products.

ACET performance versus SPY

Price and return data through 2026-10-02.

Total return is -99.7% over the past 8.7 years, 306.4 points behind SPY at 206.7%. Over the past year its total return — price change plus distributions reinvested — is -50.9%. Its deepest 1-year drawdown was 63.3%.

ACET key facts

Asset type

Stock

Asset class

Equity

Inception date

01/26/2018

Distribution frequency

None

Last close

$6.50 (as of 2026-10-02)

Market cap

$60,849,685

Average volume

164700.0

Last ex-dividend date

09/21/2018

Last payment date

10/09/2018 (as of 2018-10-09)

Beta

1.587

Payout ratio

0.0%

Forward P/E

0.0

EPS

$-10.42

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) is the latest regular payout annualized by the fund's stated frequency, divided by the last close. Issuers often publish this as “Distribution Rate” on the fact sheet. Trailing-12-month yield is the sum of distributions paid in the last 12 months, split-adjusted, divided by the last close. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ACET risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 63.3%.

Who may consider ACET — and who may not

It is a weaker fit for investors who need monthly cash flow (ACET does not currently distribute); investors hunting double-digit covered-call yields; investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

Frequently asked questions